Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 2 art units • 2 examiners • 0 of 3 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Genome International Corporation currently has 3 pending office actions in the Biotechnology & Pharmaceuticals technology area. These matters are assigned to 2 distinct examiners, providing a mix of perspectives on the company's intellectual property. This arrangement requires the applicant to handle multiple examination tracks simultaneously.
The prosecution is conducted across 2 distinct art units, which shows that the 3 pending office actions cover subject matter diverse enough to be reviewed by different specialized groups. SMITH, EMILIE ALINE is the busiest examiner for the company, currently overseeing 2 pending office actions. This concentration makes SMITH, EMILIE ALINE the most influential figure in the company's current prosecution efforts.
For a practitioner, the primary focus should be on the 2 pending office actions assigned to SMITH, EMILIE ALINE, as these represent the majority of the active workload. However, the strategy must also accommodate the 2 distinct art units and the second examiner involved in the remaining matter. Successfully navigating these 3 pending office actions requires a balanced approach that addresses the specific feedback from both of the 2 distinct examiners.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 3 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SMITH, EMILIE ALINE | 2 | 49.4% | +35.4% |
| MINCHELLA, KAITLYN L | 1 | 26.4% | +21.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18188389 | IDENTIFYING GENOME FEATURES IN HEALTH AND DISEASE | SMITH, EMILIE ALINE | — |
| 17698868 | PRECISION MEDICINE PORTAL FOR HUMAN DISEASES | SMITH, EMILIE ALINE | — |
| 17698919 | UNIFIED PORTAL FOR REGULATORY AND SPLICING ELEMENTS FOR GENOME ANALYSIS | MINCHELLA, KAITLYN L | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18188389 | IDENTIFYING GENOME FEATURES IN HEALTH AND DISEASE | SMITH, EMILIE ALINE | — |
| 17698868 | PRECISION MEDICINE PORTAL FOR HUMAN DISEASES | SMITH, EMILIE ALINE | — |
| 17698919 | UNIFIED PORTAL FOR REGULATORY AND SPLICING ELEMENTS FOR GENOME ANALYSIS | MINCHELLA, KAITLYN L | — |
| Art Unit | Apps |
|---|---|
| 1686 | 2 |
| 1685 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18188389 | IDENTIFYING GENOME FEATURES IN HEALTH AND DISEASE | SMITH, EMILIE ALINE | 1686 | §101§103§112 | Non-Final OA | — | Pending | Mar 22, 2023 |
| 17698868 | PRECISION MEDICINE PORTAL FOR HUMAN DISEASES | SMITH, EMILIE ALINE | 1686 | §101§102§112 | Non-Final OA | — | Pending | Mar 18, 2022 |
| 17698919 | UNIFIED PORTAL FOR REGULATORY AND SPLICING ELEMENTS FOR GENOME ANALYSIS | MINCHELLA, KAITLYN L | 1685 | §101§102§103§112 | Non-Final OA | — | Pending | Mar 18, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialGenome International Corporation has 3 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Emilie Aline Smith has the most, with 2 of Genome International Corporation's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
